Review argues GLP-1 drugs represent a paradigm shift in cardiovascular medicine, moving from diabetes drugs to essential cardiovascular protective therapies.
Key findingReview argues GLP-1 drugs represent a paradigm shift in cardiovascular medicine, moving from diabete
What the researchers found
Review argues GLP-1 drugs represent a paradigm shift in cardiovascular medicine, moving from diabetes drugs to essential cardiovascular protective therapies.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
GLP-1 RAs approved for T2D and obesity. Evidence reviewed for CVD, MASLD/MASH, CKD, and neurological conditions.
How the study worked
In publication.
Who was studied
Patients with neuro-cardio-metabolic disorders across multiple organ systems
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?
Pharmacology & therapeutics, 269, 108824
Citation
Arredouani, Abdelilah. (2025). GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?. Pharmacology & therapeutics, 269, 108824. https://doi.org/10.1016/j.pharmthera.2025.108824